<DOC>
	<DOCNO>NCT01613027</DOCNO>
	<brief_summary>This observational study evaluate effect disease activity safety routine clinical practice MabThera ( rituximab ) participant active seropositive rheumatoid arthritis , inadequate response one tumour necrosis factor inhibitor ( anti-TNF ) therapy .</brief_summary>
	<brief_title>An Observational Study MabThera Participants With Severe Active Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Age &gt; 18 year rheumatoid arthritis ( RA ) Seropositive participant RA ( positive rheumatoid factor ( RF ) and/or antiCitrullinated Cyclic Peptide [ CCP ] ) Active disease despite receive one TNF inhibitor Absence serious active infection Participants serious history heart failure ( class New York Heart Association [ NYHA ] IV ) severe uncontrolled heart disease Participants pregnant lactate Prior treatment MabtheraÂ® Participants receive investigational product context clinical study Participants know hypersensitivity rituximab excipients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>